Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Benoit Calderon"'
Autor:
Benoit Calderon, Léa Vazquez
Publikováno v:
Archives of Clinical and Medical Case Reports.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54542f5629b71ed0c3643dad7d1c662d
https://doi.org/10.26502/acmcr.96550508
https://doi.org/10.26502/acmcr.96550508
Publikováno v:
Bulletin du Cancer. 104:585-592
Bone metastasis are the most common cause of pain related to cancer, reducing patients' quality of life, and sometimes threatening their life-expectancy. Their management has to be pluridisciplinary, because of all the therapeutic options and the div
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5afb8950f59a44b0b391eb8ab1525b18
https://doi.org/10.1016/j.bulcan.2017.02.004
https://doi.org/10.1016/j.bulcan.2017.02.004
Publikováno v:
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-9 (2023)
Abstract Purpose Stereotactic radiotherapy (SRT) is a highly effective approach and represents the current standard of treatment for patients with limited number of brain metastasis (BM). SRT is generally well tolerated but can sometimes lead to radi
Externí odkaz:
https://doaj.org/article/7c09284dc3234d0c8feea2faaa336f24
Autor:
S. Rybikowski, Jochen Walz, Marguerite Tyran, Benoit Calderon, Gwenaelle Gravis, Slimane Dermeche, Naji Salem, Jeanne Thomassin, Marjorie Faure
Up to 40% of patients with renal cell carcinoma (RCC) with initially localized disease eventually develop metastasis following nephrectomy. The current standard of care for metastatic RCC (mRCC) is targeted therapy. However, complete response remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6a01827450d6d3967c856fba2c1485
https://europepmc.org/articles/PMC4665852/
https://europepmc.org/articles/PMC4665852/
Publikováno v:
Case Reports in Gastroenterology, Vol 15, Iss 2, Pp 742-750 (2021)
T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells
Externí odkaz:
https://doaj.org/article/6824839258874d3cbf6831f21c643224